DIFFUSION OF DILUTE FLUORESCENT MOLECULES IN NANOFABRICATED CHANNELS

稀荧光分子在纳米通道中的扩散

• 批准号: 6349439
• 负责人: SAMUEL T HESS
• 金额: $ 0.04万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6349439
• 关键词: animal tissue; bioengineering /biomedical engineering; biological products; biomedical resource; lasers

We propose to evaluate two-photon microscopy of BPD-MA to study subcellular localization under a variety of conditions. Benzoporphyrin Derivative is a second-generation photosensitizing compound currently undergoing phase II clinical trials for use in treating psoriasis, age-related macular degeneration as well as cutaneous oncology. Previous research has demonstrated that this drug is a potent sensitizer, with efficacy in cell killing demonstrated at concentrations below 200 ng/ml. Its primary subcellular target is believed to the mitochondria, where it has been demonstrated that BPD-MA can photodynamically uncouple oxidative phosphorylation in the isolated rat mitochondria. Our initial experiments have sought to optimize two-photon microscopy for observation of this drug. The two-photon cross section of BPD-MA in a liposomal preparation has recently been measured from 820-980 nm. Having measured the cross section, we will be able to evaluate a detection threshold that will then be ve rified in adherent cell culture. Organelle localization studies have been outlined are expected to proceed in the near future.

我们建议评估BPD-MA的两光子显微镜研究以研究 在各种条件下的亚细胞定位。 苯并核蛋白衍生物是第二代光敏的 目前正在进行II期临床试验的化合物用于 治疗牛皮癣，与年龄相关的黄斑变性以及 皮肤肿瘤学。 先前的研究表明这种药物 是一种有效的敏化剂，在细胞杀伤中的功效在 低于200 ng/ml的浓度。 它的主要亚细胞目标是 相信线粒体，已经证明 BPD-MA可以在光动力学上脱离氧化磷酸化 分离的大鼠线粒体。 我们的最初实验试图 优化两光子显微镜以观察该药物。 这 脂质体制剂中BPD-MA的两光子横截面具有 最近从820-980 nm测量。 测量了十字架 部分，我们将能够评估一个检测阈值 然后在粘附的细胞培养中被延长。 细胞器定位 预计将在不久的将来进行研究。